Metabolic-Fit / 100
FORM by GBY review
Elena Voss is a mother writing for mothers, not a treating clinician, and holds no medical license. Prices and terms come from the company's own published pages. This is background reading, not medical advice.
Semaglutide: $159/mo product page; $199/mo homepage; tirzepatide: $219/mo product page; $299/mo homepage. Product-page renewal prices differ from the higher homepage prices, so confirm the chosen program and renewal amount.
- Confirm HSA / FSA coverage
- Public information reviewed
- Confirm your total cost
FORM by GBY at a glance
- Semaglutide
- $159/mo product page; $199/mo homepage
- Tirzepatide
- $219/mo product page; $299/mo homepage
- Coverage
- CA, MA, VT confirmed (RI pending); other states not disclosed
- Brand-name
- Yes
How we scored FORM by GBY
Every factor comes from FORM by GBY's own published pricing, disclosures and oversight, and the six combine into the 51/100 Metabolic-Fit Score on our weighted six-factor framework. Commissions don't change a provider's score.
No postpartum or breastfeeding framing — a generic weight program.
Thin on the hormonal picture that drives many mothers' weight.
Oversight and lab support fall short of the best on our list — the review below says exactly where.
Cost is unpredictable or sits at the premium end.
Support is thin once the prescription ships.
Exit terms are the weak point: lock-in, notice periods, or a cancellation you have to chase.
How we checked this review
Semaglutide: $159/mo product page; $199/mo homepage; tirzepatide: $219/mo product page; $299/mo homepage. Product-page renewal prices differ from the higher homepage prices, so confirm the chosen program and renewal amount.
Before you sign up
What FORM by GBY's public site and signup page show before you hand over any details.
Worth knowing
- Parent brand is GBY Beauty; FORM is its provider-guided telehealth line covering GLP-1 weight loss, peptides, hair, and longevity
- Dedicated /semaglutide, /tirzepatide, /wegovy, and /zepbound pages each state a price and a 'compounded medications are not FDA approved' disclaimer where relevant
- A telehealth consent document names the clinical director's individual state licenses — California, Massachusetts, and Vermont, with Rhode Island listed as pending
- The compounded semaglutide ($299/mo) and tirzepatide ($399/mo) pages both describe all-inclusive pricing with no itemization gap
- The separate Wegovy® membership ($95/mo) is the one line here that reads like the PlushCare pattern the providers we track watches for — a membership fee with the drug's own cost not clearly itemized inside it — so it is noted, not treated as the headline price
- State coverage is only documented for one named clinician (CA, MA, VT; RI pending) in a consent document, not published as a company-wide list — treat wider availability as unconfirmed
- No named compounding pharmacy found on the public site
Pricing
| Medication | Price | Plan |
|---|---|---|
| Compounded semaglutide | $159 | InjectionProduct page $99 first month, $159 thereafter; homepage instead shows $129/$199. Confirm selected offer. |
| Compounded tirzepatide | $219 | InjectionProduct page $169 first month, $219 thereafter; homepage instead shows $199/$299. Confirm selected offer. |
| Brand semaglutide | $95 | Wegovy® membership$95/month prescribing membership; medication separate. |
Swipe the table to see plan details →
Many HSA and FSA plans cover GLP-1 telehealth — check yours. These figures are what FORM by GBY's own site disclosed at last review; this market re-prices often, so confirm the current number at the source.
What we like
- Semaglutide: $159/mo product page; $199/mo homepage; tirzepatide: $219/mo product page; $299/mo homepage.
- One of the few providers offering a path to FDA-approved brand-name Wegovy®, not compounded-only
- Dedicated, specific product pages for each drug rather than one generic weight-loss page
- Real parent-brand ownership (GBY Beauty) disclosed, not an anonymous company
The caveats
- Product-page renewal prices differ from the higher homepage prices, so confirm the chosen program and renewal amount.
- No company-wide state list published; the only concrete figures name just three states (CA, MA, VT) for one clinician
- No named compounding pharmacy disclosed
- Nothing on the site addresses pregnancy, breastfeeding, or postpartum timing
Two parts of the site show different prices
Form by GBY publishes conflicting compounded-medication offers. The semaglutide product page advertises $99 initially and $159 ongoing, while the homepage advertises $129 initially and $199 ongoing. For tirzepatide, the product page shows $169 initially and $219 ongoing, compared with $199 initially and $299 ongoing on the homepage. These are competing descriptions of the service's own offers. Request a written quote identifying which applies to your prescription rather than assuming the lowest advertisement is guaranteed.
The distinction between first and later charges matters even after that conflict is resolved. An introductory amount is not the renewal price, and the public figures do not establish that every dose or supply period has the same terms. Ask what you pay today, what the next order costs, and whether a longer commitment is required. The answer should include any shipping, supplies, and mandatory clinical charge so that you can compare the actual ongoing plan with another company's offer.
The Wegovy membership is a separate route
Form also lists a $95-per-month Wegovy prescribing membership. That is a care or prescribing charge with medication purchased separately, not a $95 complete Wegovy plan. Ask how the medication would be obtained, what it would cost under your circumstances, and what the membership includes if a prescription cannot be filled. The compounded product prices should not be used to fill in the missing branded-drug cost, because they describe different arrangements.
The website discloses GBY Beauty ownership. A connection with a beauty business helps explain the brand but does not establish medical qualifications or determine whether the care is appropriate for you. Ask which medical group and clinician provide the evaluation, how their licensure is confirmed, and how to contact them after the first order. A visually coherent consumer brand is useful for navigation, while the identity and availability of the medical team answer more substantive questions.
Do not turn one clinician's licenses into coverage
The published clinician information identifies confirmed licensure in California, Massachusetts, and Vermont, with Rhode Island described as pending. That is information about one clinician, not a complete map of the company's service area. Pending licensure is also not current licensure. Confirm that an appropriately licensed clinician can treat you where you live before completing an application or assuming the service is available because a neighboring state appears in a profile.
Form does not publicly identify the dispensing pharmacy. Obtain that identity for any compounded prescription, along with the ingredients, concentration, quantity, storage, and instructions. Compounded medications are not FDA approved and should not be assumed equivalent to an approved branded medicine. The presence of a separate Wegovy membership makes it especially important to distinguish which product is being discussed and which company or pharmacy would supply it.
What would make the offer easier to judge
Ask how follow-up is organized, whether dose changes affect the bill, and what happens if you need to stop before another order. Cancellation and refund conditions need their own clear terms; neither follows from a low introductory charge. If pregnancy planning, breastfeeding, or postpartum circumstances affect treatment, discuss them directly. General personalization and beauty-related positioning do not establish specialist maternal expertise, and the website does not supply substantive guidance resolving those questions.
Form by GBY could appeal to someone who wants to compare a compounded program with a separate branded-prescribing route through one service. The conflicting advertisements currently make that comparison harder than it should be. A useful written offer would identify the product, first payment, renewal amount, prescription quantity, and complete care arrangement. Until those are confirmed, retain both sets of published figures as a warning to clarify the price, rather than promoting one of them as a settled universal rate.
The bottom line for mothers
Best for: Readers who can compare the full payment commitment and confirm the renewal amount before choosing a plan.
Alternatives to FORM by GBY
These are partners — we may be paid if you sign up through these links. The full list has every provider we cover, partner or not.
- Visit CoreAge Rx86
Metabolic-Fit / 100
CoreAge RxFeatured partnerCoreAge's officially linked public offer advertises compounded semaglutide at $79/month and tirzepatide at $129/month across doses, with care and overnight shipping included. It describes one-time purchases without a required subscription. Main navigation still shows semaglutide from $99; confirm your prescription quantity and total, and read the refund limits before paying.
- Visit RxSpan MD57
Metabolic-Fit / 100
RxSpan MD is a genuinely well-disclosed service wrapped in marketing that undercuts it. The disclosure: four compounding pharmacies named with phone numbers, two lead physicians named with NPI numbers that verify as active MDs, flat pricing posted before any intake, both compounded and real FDA-approved brand GLP-1s on one platform, and oral capsules for anyone who won't inject. Compounded semaglutide is $249 a month and tirzepatide $329, with brand Zepbound at $1,069, Ozempic at $1,299 and Wegovy at $1,349. The marketing is the problem. Its testimonials still name a different company — one patient describes what she 'expected from CareGLP' — and the doctors quoted in them are not the clinicians the same page names as its medical team. The homepage is built around a board-certified plastic surgeon who founded the practice but is licensed in California only and isn't the prescriber. Its compounded prices also sit above the typical price we track, and the oral capsules cost the same or more than the injections.
- Visit Eden47
Metabolic-Fit / 100
FDA warning letter #728279 (June 2026), which names Eden's website — read that first. Then read the price twice: the advertised $99 is medication alone, with a required $99-a-month membership on top.
Providers like FORM by GBY
Keep comparing FORM by GBY
Head-to-head & alternatives
Ranked boards
- Best GLP-1 for women
- Best GLP-1 for PCOS & insulin resistance
- Best GLP-1 for perimenopause
- Best GLP-1 while breastfeeding (safety-first)
- Cheapest GLP-1 programs
- Compounded tirzepatide providers
- Cheapest tirzepatide online
- Cheapest semaglutide online
- Where to get Zepbound online
- Semaglutide vs tirzepatide: which is right for you
FORM by GBY, answered
- Is 'FORM by GBY' the same company as the 'Form Health' review on this site?
- No — they're unrelated. Form Health is a separate, previously-reviewed company. FORM by GBY is the telehealth line of GBY Beauty, a different business, verified independently for this review.
- What does FORM by GBY cost?
- Semaglutide: $159/mo product page; $199/mo homepage; tirzepatide: $219/mo product page; $299/mo homepage. Product-page renewal prices differ from the higher homepage prices, so confirm the chosen program and renewal amount.
- Is FORM by GBY available in my state?
- FORM doesn't publish a company-wide state list. The only concrete figures we found were in a telehealth-consent document naming one clinician's individual licenses — California, Massachusetts, and Vermont, with Rhode Island pending. Don't assume broader availability without confirming directly.
Pricing, states and verification reflect FORM by GBY's public disclosures at last review; the Metabolic-Fit Score is our editorial judgment per the published methodology. This is background reading, not medical advice — GLP-1 medications are not established as safe in pregnancy or breastfeeding. See our medical disclaimer and how we're funded.